ЯН Эжен Мари Жозеф (BE),КЕКЕН Филип Рене Ирена (BE),ВОРСПУЛС Жоди Фирмин Марселине (BE),ФОРЕ Анне (BE),АРКЕНАУ-МАРИК Элизабет (DE),БАРНШАЙД Лутц (DE),БАРТОЛОМОЙС Иоганнес (DE),ФРЕВЕЛЬ Марк (DE),ГАЛИА
申请号：
RU2010135200/15
公开号：
RU2010135200A
申请日:
2009.01.23
申请国别(地区):
RU
年份:
2012
代理人:
摘要：
1. A dosage form with a controlled release of the pharmacologically active composition (A) contained therein, the dosage form having a tensile strength B1 of at least 500 N in the tensile direction E1 and a tensile strength B2 of less than 500 N in the tensile direction E2. ! 2. The dosage form according to claim 1, where the total surface S of the dosage form in mm2 satisfies the following requirements:! ! where A represents 4,5 and! W is the total weight of the dosage form in mg. ! 3. The dosage form according to claim 2, where A is 6.2. ! 4. The dosage form according to claim 1, which contains a polymer (C). !5. The dosage form according to claim 4, where the polymer (C) has a weight average molecular weight of at least 100,000 g / mol-1. ! 6. The dosage form according to claim 4, where the polymer (C) is hydrophilic. ! 7. The dosage form according to claim 4, where the polymer (C) includes polyalkylene oxide and / or at least one derivative of cellulose ether. ! 8. The dosage form according to claim 7, where the cellulose ether derivative is selected from the group consisting of hydroxypropyl methylcellulose and / or hydroxypropyl cellulose. ! 9. The dosage form according to claim 7, where the polyalkylene oxide is a polyethylene oxide. ! 10. The dosage form according to claim 9, where the polyethylene oxide has a molecular weight in the range of from about 500,000 g / mol to about 1,500,000 g / mol. ! 11. The dosage form according to claim 4, which further includes polyalkylene glycol. ! 12. The dosage form according to claim 11, where the polyalkylene glycol is a polyethylene glycol. ! 13. The dosage form according to claim 1, which is resistant to abuse and where the pharmacologically active composition (A) has sweat1. Лекарственная форма с контролированным высвобождением фармакологически активного состава (А), содержащегося там, причем лекарственная форма имеет предел прочности на разрыв B1 по крайней мере 500 Н в направлении растяжения Е1 и имеет предел про
